IQV at a glance
IQVIA (IQV, SEC CIK 1478242) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on July 28, 2026, an 8-K current report on September 23, 2026 and Form 4 insider filings as recently as September 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), IQVIA (IQV) reported revenue of $16.3 billion (up 5.9% from FY2024) and net income of $1.4 billion. Diluted EPS was $7.84.
- As of June 30, 2026, 44 institutional investment managers tracked by SignalX reported holding IQVIA (IQV) shares worth $13.5 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Berkshire James G. on September 2, 2026 of 2,668 shares at $261.33 per share.
- In the last 90 days, IQV insiders reported 0 open-market purchases ($0) and 9 open-market sales ($29.9M) on Form 4, a net sale of $29.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $16.3B
- +5.9% vs prior year
- Insiders · 90 days
- 0 buys · 9 sells
- Net −$29.9M
- 13F holders
- 44 funds
- $13.5B · +2 vs prior quarter
- Latest 8-K
- Sep 23, 2026
- Item 1.01 · Item 2.03
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Global clinical development and commercial solutions services for biopharmaceutical industry
- Emphasis on risks from client consolidation reducing service volumes and revenue loss post-mergers in clients’ industries
- Increased focus on managing complex international regulatory, economic, and political risks impacting multi-country clinical trials
- Workforce strategy: Leveraging global hiring in lower-cost countries to improve efficiency amid competition and wage inflation pressures
- Noteworthy sustainability risk disclosure: Evolving global regulatory and stakeholder demands on sustainability could raise costs and reputational risks
Risk Factors
- Regulatory risk: Compliance with HIPAA and EU GDPR, with potential fines and penalties under US Dept. of Health and Human Services and EU authorities
- Geopolitical risk: Increased cyberattack threat from state-sponsored actors causing data compromise and operational disruption in global IT systems
- Supply chain risk: Dependence on third-party suppliers for clinical trial materials and data; supplier restrictions or failures may materially harm operations
- Competitive risk: Risk of lost or delayed large contracts due to clients shifting business to competitors or internal resources in biopharma services
- Financial risk: Senior Secured Credit Facilities and note indentures restrict financing and operational flexibility, potentially limiting growth initiatives
Management Discussion & Analysis
- Revenue $16,310M in 2025, up 5.9% (+$905M) YoY; Technology & Analytics Solutions +7.6% ($466M), Research & Development Solutions +4.3% ($369M), Contract Sales & Medical Solutions +9.7% ($70M)
- Operating profit $2,182M in 2025, down 0.9% from $2,202M in 2024; segment profit: Technology & Analytics $1,595M (+4.8%), R&D $1,873M (-3.9%), Contract Sales $48M (+2.1%)
- Best performing segment: Technology & Analytics Solutions revenue growth 7.6%, profit +4.8%; Worst performing segment: Research & Development Solutions profit decline by 3.9% despite revenue growth
- Operating cash flow $2,654M; $1,714M net cash invested in acquisitions; cash and equivalents $1,980M (+$278M); $1,769M remaining stock repurchase authorization; total debt $15,800M, compliant with covenants
- Management guidance: ongoing restructuring to streamline operations; expected continued integration of segments beginning 2026; risks from macroeconomic uncertainty, client cautiousness, and foreign currency fluctuations
AI summary of the IQV 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $4,368M, up $351M or 8.7% YoY
- Effective tax rate 19.9% vs 17.3% YoY
- Best segment Research & Development Solutions revenue $2,575M, up 8.8%; profit $526M, up 11.2%
- Cash $1,909M at June 30 vs $1,980M at December 31, 2025
- Restructuring costs $63M vs $32M YoY; actions expected through 2026 and 2027
Risk Factors
- No risk-factors section provided; submitted text covers equity repurchases, exhibits, and signatures
- Repurchase authorization increased $2,000 million on May 7, 2026, reaching $15,725 million
- $950 million spent repurchasing 5.5 million shares during six months ended June 30, 2026
- New 4.625% Senior Notes due 2033 indenture dated June 11, 2026
- Remaining repurchase authorization $2,819 million as of June 30, 2026
AI summary of the IQV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- $2.0B senior notes issued at 6.375% interest, maturing March 15, 2034
- Proceeds refinance 5.000% notes due 2026 and repay revolving credit borrowings
Item 2.03: Creation of a Direct Financial Obligation
- Indenture dated September 23, 2026 creates a formal debt framework for IQVIA Inc.’s notes
- Certain IQVIA subsidiaries provide guarantees, potentially broadening creditor claims across the group
Item 8.01: Other Events
- IQVIA subsidiary plans $2.0B senior-notes issuance due 2034 at 6.375% annual interest
- Proceeds earmarked to redeem $2026 notes, reduce revolving-credit debt, and cover offering expenses
Item EX-99.1: Item EX-99.1
- $2.0B senior notes offering due 2034, subject to market and customary closing conditions
- Proceeds earmarked to redeem 5.000% notes due 2026 and repay revolving credit facility borrowings
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued July 28, 2026
AI summaries of IQV 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for IQV
Don't miss the next IQV filing
- Alerts as it files. A push when IQV files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut IQV, by share count.
- Ask anything. An AI agent that reads every IQV filing and answers with sources.
IQV alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Berkshire James G. | Sell | Sep 2, 2026 | 2,668 | $261.33 |
| Berkshire James G. | M | Sep 2, 2026 | 5,381 | $131.82 |
| Berkshire James G. | M | Sep 2, 2026 | 5,381 | $131.82 |
| Berkshire James G. | D | Sep 2, 2026 | 2,713 | $261.54 |
| STAUB W RICHARD | Sell | Aug 3, 2026 | 5,500 | $232.68 |
| Patel Bhavik | Sell | Jul 31, 2026 | 1,855 | $235.27 |
| BOUSBIB ARI | Sell | Jul 29, 2026 | 53,191 | $244.78 |
| BOUSBIB ARI | M | Jul 29, 2026 | 156,206 | $78.21 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $15.0B | $15.4B | $16.3B |
| Operating Income | $2.0B | $2.2B | $2.2B |
| Net Income | - | $1.4B | $1.4B |
| Op. Margin | 13.2% | 14.3% | 13.4% |
| Net Margin | - | 8.9% | 8.3% |
| Balance Sheet | |||
| Total Assets | $26.7B | $26.9B | $29.9B |
| Equity | $6.1B | $6.1B | $6.5B |
| ROE | - | 22.6% | 20.9% |
| Per Share | |||
| EPS | $7.29 | $7.49 | $7.84 |
| Cash Flow | |||
| Operating CF | $2.1B | $2.7B | $2.7B |
Source: XBRL data in IQVIA (IQV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate IQV share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 44 | $13.48B |
| Q1 2026 | 42 | $11.73B |
| Q4 2025 | 42 | $15.80B |
| Q3 2025 | 39 | $13.85B |
| Q2 2025 | 38 | $10.79B |
| Q1 2025 | 36 | $9.19B |
| Q4 2024 | 32 | $8.68B |
| Q3 2024 | 28 | $4.34B |
- Franklin Resources+1.60M (+317%)
- Goldman Sachs Group+772.5K (+66%)
- JPMorgan Chase & Co+732.1K (+14%)
- AQR Capital Management+296.0K (+24%)
- Millennium Management+248.5K (+93%)
- Ameriprise Financial−837.7K (-52%)
- FMR LLC (Fidelity)−637.5K (-34%)
- BlackRock−477.8K (-3%)
- T. Rowe Price Group−390.6K (-53%)
- Two Sigma Investments−171.8K (-78%)
- D.E. Shaw & Co+466.2K
- Blackstone Group+2.1K
- StoneX Group Inc.+1.5K
- Marex Group plc−4.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 301 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
IQV filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 31, 2026 | - | - | - |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 10-Q | Jul 28, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| SC 13G | Apr 30, 2026 | - | - |
Related Health Care companies
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- CRL · Charles River LaboratoriesServices-Commercial Physical & Biological Research
- INCY · IncyteServices-Commercial Physical & Biological Research
- MXCT · MAXCYTE, INC.Services-Commercial Physical & Biological Research
- NRC · NATIONAL RESEARCH CORPServices-Commercial Physical & Biological Research
- OABI · OmniAb, Inc.Services-Commercial Physical & Biological Research
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
IQV SEC filings: frequently asked questions
Are IQV insiders buying or selling?
In the last 90 days, IQVIA (IQV) officers, directors and 10% owners reported no open-market purchases and 9 open-market sales worth $29.9 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold IQV stock?
As of June 30, 2026, the largest IQVIA (IQV) holders among the 13F filers tracked by SignalX were BlackRock ($2.8 billion), Vanguard Capital Management LLC ($2.1 billion), State Street Corp ($1.5 billion), Vanguard Portfolio Management LLC ($1.4 billion), JPMorgan Chase & Co ($1.2 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was IQV's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), IQVIA (IQV) reported revenue of $16.3 billion (up 5.9% from FY2024) and net income of $1.4 billion. Diluted EPS was $7.84. The figures come from the XBRL data in the 10-K.
What are the main risks in IQV's latest 10-K?
In the 10-K filed February 17, 2026, IQVIA (IQV) flagged: Regulatory risk: Compliance with HIPAA and EU GDPR, with potential fines and penalties under US Dept. of Health and Human Services and EU authorities. Geopolitical risk: Increased cyberattack threat from state-sponsored actors causing data compromise and operational disruption in global IT systems. (AI summary of the Risk Factors section.)
What did IQV report in its latest 8-K?
IQVIA (IQV) filed an 8-K on September 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation). $2.0B senior notes issued at 6.375% interest, maturing March 15, 2034.
What are the latest IQV SEC filings?
IQVIA (IQV) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on July 28, 2026, an 8-K current report on September 23, 2026 and a Form 4 insider filing on September 4, 2026.
What is IQV's SEC CIK number?
IQVIA (IQV)'s SEC Central Index Key (CIK) is 1478242. EDGAR lists every IQV filing under that number.
Ask anything about IQV
The research agent reads IQV's filings, financials, insider trades and 13F holders, then answers with sources.